Quantitative expression and localization of GABAB receptor protein subunits in hippocampi from patients with refractory temporal lobe epilepsy by Sheilabi, MA et al.
 1 
 
QUANTITATIVE EXPRESSION AND LOCALIZATION OF GABAB 
RECEPTOR PROTEIN SUBUNITS IN HIPPOCAMPI FROM PATIENTS WITH 
REFRACTORY TEMPORAL LOBE EPILEPSY 
 
Mariam A. Sheilabia, Dev Battacharyyab, Laura Caetanoa,#, Maria Thomc , Markus 
Reuberd,  , John S. Duncane, and Alessandra P. Princivallea,f*.  
a Biomolecular Sciences Research Centre, Sheffield Hallam University, Howard Street, 
Sheffield, S1 1WB, UK 
b  Neurosurgery, Sheffield Hallamshire Hospital, Glossop Road, Sheffield, S10 2JF, UK. 
c Department of Neuropathology, e Department of Clinical and Experimental Epilepsy,  
Institute of Neurology, UCL, Queen Square, London. 
d Academic Neurology Unit, University of Sheffield, Royal Hallamshire Hospital, Glossop 
Road, Sheffield, S10 2JF. 
f Division of Neuroscience, Department of Pharmacology, Medical School, University of 
Birmingham, Birmingham, B15 2TT, UK.  
 
 
 
 
 
*Correspondence to Alessandra P. Princivalle 
Biomolecular Research Centre, Sheffield Hallam University, Sheffield, S1 1WB, UK. 
e-mail: a.p.princivalle@shu.ac.uk  
#Present address: Southampton General Hospital, Centre for Biological sciences, SO16 
6YD. 
 
 
 
 2 
 
ABSTRACT 
This study investigates GABAB protein expression and mRNA levels in two specimens 
from patients with TLE, secondary to hippocampal sclerosis, removed during epilepsy 
surgery (sclerotic hippocampal samples) TLE-HS, and tissue from the healthy, non-
spiking ipsilateral superior temporal gyrus (TLE-STG); and hippocampal tissue specimen 
from individuals with no history of epilepsy (post-mortem controls, PMC).  
mRNA expression of GABAB subunits was quantified in PMC, TLE-STG and TLE-HS 
specimens by qRT-PCR. Qualitative and quantitative Western blot (WB) and 
immunohistochemistry techniques were employed to quantify and localize GABAB proteins 
subunits. 
qRT-PCR data demonstrated an overall decrease of both GABAB1 isoforms in TLE-HS 
compared to TLE-STG. These results were mirrored by the WB findings. GABAB2 mRNA 
and protein were significantly reduced in TLE-HS samples compared to TLE-STG; however 
they appeared to be upregulated in TLE-HS compared to the PMC samples. IHC showed 
that GABAB proteins were widely distributed in PMC and TLE-HS hippocampal sections 
with regional differences in the intensity of the signal.  The co-localisation of GABAB1(a-b) 
and GABAB2 seemed to support the idea that the receptor is heterodimeric. The higher 
expression of mature GABAB protein in TLE-HS than PMC is in agreement with previous 
studies. However, these findings could be due to post-mortem changes in PMC specimens. 
Possibly the TLE-STG samples examined here represent a better ‘control’ tissue. If so, 
TLE-HS samples would be characterised by lower than expected GABAB expression. This 
interpretation would provide a better explanation for functional studies suggesting reduced 
inhibition in TLE-HS tissue due to attenuated GABAB currents.  
 
KEYWORDS: human temporal lobe epilepsy, hippocampal sclerosis, GABAB qRT-PCR, 
quantitative Western blot, immunohistochemistry. 
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1. INTRODUCTION 
The main inhibitory neurotransmitter in the mammalian central nervous system (CNS), -
aminobutyric acid (GABA), plays important roles in regulating neuronal activity, plasticity, 
and pathogenesis. Its action is mediated through distinct receptor types: ionotropic (GABAA 
and GABAC) and metabotropic (GABAB). Both GABAA and GABAB receptors have been 
implicated in many important physiological functions and pathological conditions in the 
brain (Mott and Lewis 1994; Misgeld et al. 1995, Bowery 1997; Deisz et al.1997; Bettler et 
al. 1997). 
GABAB receptors have been demonstrated at both pre- and postsynaptic sites of both 
excitatory and inhibitory neurones (Chen et al. 2004). Presynaptic receptor stimulation 
reduces the evoked release of GABA and other neurotransmitters, whereas postsynaptic 
GABAB receptor activation increases neuronal K+ conductance to generate long-lasting 
inhibitory postsynaptic potentials (IPSPs). 
Along with other findings, previous pharmacological and physiological studies have 
suggested the existence of two distinct GABAB1 receptor subtypes at pre- and postsynaptic 
sites and in different cells types and brain structures (Bowery 1997; Deisz et al.1997; Dutar 
and Nicoll 1988; Pitler and Alger 1994). The evidence for two different GABAB1 receptor 
isoforms (GABAB1a and GABAB1b) was first characterised by Kaupmann and colleagues 
(1997). A second subunit was subsequently characterised (Kaupmann et al. 1998; Jones 
et al. 1998; White et al. 1998).  
 The distribution of GABAB1 receptors in human hippocampus has been demonstrated with 
receptor binding autoradiography (Princivalle et al. 2002). Expression of GABAB1 mRNA in 
the rat CNS, human hippocampus and spinal cord has been established by radiolabelled 
riboprobes recognising the two GABAB1 mRNA variants (Kaupmann et al. 1997; Benke et 
al. 1999; Liang et al. 2000; Towers, et al. 2000). The expression of GABAB2 messengers 
has also been described in rat brain (Kaupmann et al. 1998; Jones et al. 1998). In addition 
GABAB1 (a/b) and GABAB2 immunoreactivity has been demonstrated in the rat CNS (Ige et 
al. 2000; Princivalle et al. 2000a; 2000b; 2001; Charles et al. 2001). Nevertheless, it is still 
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unclear how the two GABAB1 variants and the GABAB2 mature proteins are distributed in 
different neuronal regions and cell types in human brain tissue such as the hippocampus, 
or how the transcription of GABAB1 and GABAB2 may be affected by pathological states 
such as epilepsy. 
Temporal lobe epilepsy (TLE) is the commonest and best researched drug-refractory focal 
epilepsy. Electrophysiological evidence has demonstrated that there is a lack of inhibition 
in TLE due to the abolished slow component of GABAB receptor-mediated IPSPs (Mangan 
and Lothman, 1996, Teichgrӓber et al. 2009). In addition, there is pharmacological and 
physiological evidence that GABAB is impaired in animal models of TLE (Chandler et al. 
2003; Furtinger et al. 2003a; Mares and Kubová 2015; Leung et al. 2016). However, the 
localization and quantitative expression of GABAB isoforms and subunits have not yet been 
elucidated in animal models or in human TLE. 
This study aimed to examine how possible differences in GABAB1a, GABAB1b and GABAB2 
mRNA and protein expression may contribute to the impaired GABAB mediated currents 
reported in TLE (Straessle et al. 2003; Rocha et al. 2015). We investigated whether GABAB 
protein expression showed a reduction in the hippocampal tissue of patients with mesial 
temporal sclerosis (TLE-HS) compared to tissue taken from the same patients’ superior 
temporal gyrus (TLE-STG) and post-mortem hippocampal control (PMC) tissue from 
individuals with no history of epilepsy.  
 
2. MATERIALS AND METHODS 
2.1. Patient tissue collection and clinical data  
The majority of surgical samples were obtained from the Royal Hallamshire Hospital (R&D 
approval STH15210). The post-mortem immunohistochemistry samples were obtained 
from The National Hospital for Neurology and Neurosurgery.  All samples were obtained 
with the understanding and the written consent of each patient. The sample collection 
procedure fully conformed with the Code of Ethics of the World Medical Association 
(Declaration of Helsinki), British Medical Journal (1964), and the Institute of Neurology Joint 
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Research Ethics Committee [Ethics Committee Protocol Pro-Forma (January 1998)]. The 
study was approved by the South Yorkshire Research Ethics Committee (08/H1310/49). 
The surgical sclerotic human hippocampal tissue (TLE-HS) and non-sclerotic (TLE-STG) 
samples were obtained from patients with medically refractory TLE, undergoing surgical 
resection. Only patients with TLE secondary to unilateral hippocampal sclerosis were 
included. Clinical and demographic information about these patients is in Table 1.  In 
summary, the median age of patients was 38 years (range 22-63). Patients had had 
epilepsy for a median of 23 years prior to surgery (range 2-53).  Patients were taking a 
median of 3 antiepileptic drugs at the time of surgery. The patients had simple or complex 
partial seizures and 36% of them had also generalized tonic clonic seizures. 26% of 
patients had a history of febrile seizures. Only 14 from 23 patients (60%) of patients were 
seizure free after 1 year of epileptic surgery. The excision of the samples was based on 
pre-surgical clinical evaluation including interictal and ictal EEG studies and magnetic 
resonance imaging (MRI) in all cases. Each sample was divided into two parts, one part 
was snap frozen (Kingsbury et al. 1996) and stored at -80°C until RNA and protein 
extraction were performed. The second part of the sample was fixed for histopathological 
analysis and all pre-operative diagnoses of HS were confirmed after surgery by 
histopathological examination based on established diagnostic criteria (Thom at al. 2002), 
and immunohistochemistry experiments. The TLE-STG specimens were taken from the 
superior temporal gyri which looked structurally healthy on MRI, and had not been shown 
to generate ictal or inter-ictal epileptiform activity during pre-surgical 
electroencephalographic monitoring. If this kind of samples does not follow the above 
criteria they were not collected.  
The flash-frozen post-mortem hippocampal samples were obtained from the UCL Brain 
Bank (08/H0718/54). They were from individuals with no previous medical history of 
neurological or psychiatric disease (Table 2). At autopsy the hippocampi were dissected, 
pH was checked to be between 6 and 7, and the samples were flash frozen and stored at 
-80°C. 
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2.2. Quantitative real-time polymerase chain reaction (qRT-PCR) 
2.2.1. RNA extraction: The total RNA was extracted from samples using SV Total RNA 
Isolation System kit according to manufacturer's instructions (Promega). Briefly, the 
hippocampal tissue lysates were prepared by adding 1 ml RNA lysis buffer to 342 mg of 
tissue weight. The tissue lysates were diluted with SV RNA dilution buffer and RNA was 
then adsorbed to a silica membrane-based column where it was purified by a spin method. 
RNA was subjected to DNase treatment, washed and eluted with 100 µl of Nuclease-free 
water. The RNA purity was checked by the NanoDrop-1000 spectrophotometer, and the 
RNA integrity was checked by 1% agarose gel electrophoresis. 
2.2.2. cDNA synthesis: Complementary DNA (cDNA) was synthesised by using the 
Superscrpit III first strand synthesis system (Life Technologies, 18080-051) according to 
the manufacturer's recommendation. Starting from 1µg of total RNA, cDNA was 
synthesised by using 50 µM of oligo (dT)20 primer, 40 U of RNaseOUT and 200 U of 
Superscrpit III reverse transcriptase enzyme. The cDNA was then purified by using 
QIAquick PCR purification kit (Qiagen, 28104) and quantified with the NanoDrop-1000 
spectrophotometer. 
2.2.3. qRT-PCR: The mRNA expression of GABAB1 and GABAB2 subunits was investigated 
by qRT-PCR in 26 TLE-HS and 11 TLE-STG specimens (Table 1) and 10 post-mortem 
samples (Table 2). The qRT-PCR was performed on a StepOnePlus™ Real-Time PCR 
System (Applied Biosystems) using TaqMan gene expression assays (Table 3).  A 10 µl 
volume of PCR reaction mix was prepared by combining template cDNA sample, TaqMan 
Universal PCR Master Mix (Applied Biosystems, 4352042) and TaqMan gene expression 
assays (Life Technologies). Cyclophilin A (PPIA) and cyclin-dependent kinase inhibitor 1B 
(CDKN1B) were selected as reference genes for our study as they were among the most 
stably expressed genes in TLE (Wierschke et al. 2010). 
2.2.4. Data analysis: Results were analysed using the 2–ΔCt method and presented as 
relative gene expression normalised to the average threshold cycle of the two 
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housekeeping genes. The GraphPad Prism 6 software for Windows, version 6.05 was used 
for the statistical analysis (San Diego, CA, USA; www.graphpad.com). The Shapiro-Wilk W 
test was performed to test the normality of the data. The Kruskal-Wallis with Conover-Inman 
post hoc analysis test was used to identify significant differences between samples (P < 
0.05). 
2.3 Quantitative two colour Western blot (qWB) 
2.3.1. Protein extraction and quantification: The hippocampi tissues were homogenised 
at 4°C in CelLyticTM (C3228, Sigma) and protease inhibitor cocktail (P8340, Sigma). The 
lysate was centrifuged twice at 500 XG for 15 minutes at 4°C. The supernatant was 
centrifuged at 20000 XG for 40 minutes at 4°C and pellet was suspended in 50mM TrisHCl 
buffer pH 7.5 (TBS). The total protein was then quantified by Bicinchoninic acid protein 
assay kit according to the manufacturer's protocol (BCA1, B9643, Sigma-Aldrich). 
2.3.2. Quantitative WB:  The GABAB receptor subunits were investigated by qWB in 9 
TLE-HS, 6 TLE-STG, and 4 PMC samples (according to sample availability). 20 µg of 
protein was loaded on 8% sodium dodecyl sulphate-polyacrylamide gel for electrophoresis 
(SDS-PAGE). The separated proteins were electro-transferred onto a nitrocellulose 
membrane, which was washed briefly in phosphate buffered saline (PBS) for few minutes. 
The membranes were then blocked with 5% w/v non-fat dry milk (NFDM) in PBS and 0.1% 
Tween 20 (PBST) for 1 hour at room temperature (RT). Then they were incubated with 
primary diluted antibodies (Table 4) over night at 4°C with gentle shaking. A generous 
amount of 0.1% PBST buffer was used to wash the membranes 4 times for 5 minutes each. 
Then membranes were incubated with infrared-labelled secondary antibodies for 1 hour at 
RT followed by 4 washes with 1X PBS for 5 minutes each. The membranes were scanned 
on an Odyssey infrared imaging system (LI-COR, Biosciences, NE, U.S.A.). The 700nm 
and 800nm channel scanning intensities were set to 4 and 6 respectively. The images 
acquired were quantified on the Odyssey software (version 1.2) according to the software 
manual and Picariello et al. (2006). 
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2.3.3. Data analysis: GABAB1(a-b), and GABAB2 bands intensities were normalized to β-actin 
to eliminate any loading variation. The GraphPad Prism 6 software version 6.01 for 
Windows was used for all the statistical analysis (San Diego, CA, USA). The Shapiro-Wilk 
W test was performed to test the normality of the data. The Kruskal-Wallis with Conover-
Inman post hoc analysis test was used to identify significant differences between samples 
(P < 0.05). 
2.4 Immunohistochemistry (IHC)  
2.4.1. Brain sections preparation: Sections (10 µm) of paraffin-embedded human 
hippocampal tissue were cut by a microtome, mounted onto charged microscope slides 
(BDH Superfrost Plus) and stored with desiccant in plastic slide boxes at RT until required. 
2.4.2. Tissue pre-treatment and application of antibodies 
The immunohistochemistry antibodies sub-types specificity to human GABAB1a, GABAB1b 
or GABAB2 was previously tested (Calver et al. 2000). Immunohistochemistry (IHC) was 
conducted on 7 TLE-HS (Table 1) and 5 PMC specimens (Table 2) according to specimen 
availability. Following antigen retrieval, sections were rinsed in PBS, endogenous 
peroxidase activity blocked by incubation with hydrogen peroxide (0.3% in PBS) for 30 
minutes, and followed by a rinse in fresh PBS. Sections were then incubated with normal 
goat serum (NGS) (1:10 in PBS) for 75 minutes, and subsequently overnight at 4°C with 
the primary antibodies (Table 4) respectively in PBS containing 1% NGS. 
Following incubation with primary antibodies, the sections were washed with fresh PBS for 
1 hour then incubated with secondary biotinylated antibodies (Table 4) for 75 minutes, 
rinsed for 1 hour in PBS and incubated with the avidin-biotin peroxidase complex (ABC; 
Vector) for 75 minutes. Peroxidase staining was performed by incubating the sections in 
0.002% 3.3'diaminobenzidine - 0.08% nickel ammonium sulphate and 0.002% H2O2 in 
50mM Tris buffer, pH 7.6. The sections were dehydrated, and cover-slipped with diethyl-
pyro carbonate (DPX). 
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2.4.3. Microscope visualization and quantitative IHC (qIHC) 
Neuronal counting was performed as before (Princivalle et al. 2002; 2003). The number 
and intensity of GABAB receptor subunits were quantified in pyramidal and granular cells in 
TLE-HS and PMC IHC sections using the Q-Capture Pro 7™ (QCapture 10, 2010) 
connected to an Olympus BX60 microscope.  
In order to quantify the immunosignals of the GABAB1 receptor isoforms and subunit, 13 
sections from TLE patients and 5 from PMC were analysed. The microscope amplification 
used for quantification of each slide was 10 (ocular lens) x 20 (objective lens), giving a total 
amplification of 200x. For each slide 6 images of the area of interest (hippocampus) were 
captured. The raw relative optical density (ROD) of GABAB immunosignals was determined 
using the measuring tools of Q-Capture Pro 7™ software. The pyramidal cells were marked 
with a yellow triangle and granular cells with a blue square measuring tool. The ROD was 
normalized by subtracting the background (calculated by averaging 10 background spots 
in each slide). To correct for neuronal loss, ROD per neuron was calculated by dividing the 
total ROD on the number of GABAB immunopositive neurons. 
 
3. RESULTS 
3.1. qRT-PCR 
The correlation between PMC mRNA samples versus age and post-mortem interval in 
figure 1 demonstrates no correlation between the mRNA findings and these factors which 
could have influence the mRNA expression. The data from qRT-PCR, obtained from the 
whole resected hippocampi, show a very similar trend for both GABAB1 and GABAB2 
subunits. The comparison of TLE-HS and the PMC samples reveals no difference in 
GABAB1 subunit expression between the groups, but an increased GABAB2 expression in 
the TLE-HS tissue. In contrast, the comparison of TLE-HS with the TLE-STG samples 
showed a lower level of expression of both GABAB in the TLE-HS tissue (see Figure2). 
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3.2. Qualitative and Quantitative WB 
Figure 3A shows a double-labelled Western blot image demonstrate a fairly consistent level 
of β-actin expression in the three study groups. However, there is a clear gradient of the 
expression of all three GABAB variants across the study groups. These proteins are 
expressed most strongly in TLE-STG, less strongly in TLE-HS and least strongly in PMC 
tissue. The data obtained by quantitative double-labelled analysis (Figure 3B) follows the 
same trend although differences between the TLE-HS and the TLE-STG comparisons were 
only significant for GABAB2. 
3.3. Distribution and comparison of GABAB receptor protein immunoreactivity in 
PMC and TLE-HS hippocampi 
GABAB1a, GABAB1b and GABAB2 receptor proteins appeared to have a similar location in 
the TLE-HS and PMC hippocampal sections; furthermore, no evidence of single subunit 
labelling was observed in the hippocampal subregions of either sample category (Figure 4 
A-F). In PMC cases GABAB2 and GABAB1b exhibited the highest and the lowest 
immunoexpression respectively. All the three proteins displayed the highest expression in 
the dentate gyrus (DG) followed by the different cornu ammonis (CA) areas (all with 
comparable immunointensity), and the subiculum, which showed the lowest level of 
immunopositivity.  
Figure 5A shows the total number of pyramidal and granular cells per mm3 highlighting 
neuronal loss in the TLE-HS. 5B and 5C show the percentage of GABAB positive pyramidal 
and granular neurons respectively. Whereas immunopositivity to GABAB1 was greater in 
pyramidal PMC than TLE-HS cells it was lower in granular PMC than TLE-HS cells. In 
contrast, GABAB2 immunopositivity was more marked in TLE-HS than PMC in both types 
of neurons. Figures 5D and 5E show semi-quantitative immunosignal measurements 
demonstrating the intensity of immunopositivity per remaining neuron in PMC and TLE-HS. 
The GABAB2 signal intensity is higher while GABAB1a is lower in TLE-HS patients compared 
to PMC in both pyramidal and granular cells. The comparison of GABAB1b intensity between 
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TLE-HS and PMC cells on the other hand showed higher GABAB1b intensity in granular and 
lower intensity in pyramidal cells (resulting not only from the image shown but from the 
averaged analysis of 5 patients); however, these differences did not achieve significance 
in the small number of samples available for comparison. 
Figure 6 and 7 show how representative pyramidal cells in CA areas and DG granular 
neurones reacted with the three antibodies for GABAB1a, GABAB1b and GABAB2 at higher 
magnification. The immunosignal proved to be specific for all three antibodies. The left 
panel in Figure 6 represents pyramidal neurones in of CA1. The immunoreactivity was 
mainly expressed by the cell bodies and apical dendrites; there was no nuclear staining at 
all, either in PMC or in the TLE-HS sections. The main difference between PMC and TLE-
HS CA1 was the intensity of immunoreactivity in most of the neuronal cells. GABAB1a and 
GABAB2 immunoreactivity appeared stronger in a few neurones, whilst the GABAB1b 
immunosignal seemed fainter in the majority of TLE-HS compared to PMC neurons. Figure 
6, right panel shows CA2 pyramidal neurones. The immunosignal, for all three antibodies, 
was confined to the cell bodies and apical dendrites in the control specimen. In the TLE-
HS hippocampi there was neuronal loss. Furthermore the remaining neurones appeared 
smaller and contracted and the immunosignal seemed stronger in the cytoplasmic 
membrane. Figure 7, left panel displays pyramidal neurones in CA3. Immunopositivity was 
mainly confined to the neuronal bodies with almost no apical dendrites being 
immunolabelled with any of three antibodies in the PMC hippocampus. In TLE-HS neuronal 
loss was evident, the cells appeared to be smaller, and the immunoreactivity was present 
on the cytoplasmic membrane. There was also an apparent proliferation of glial cells as 
reported in literature (Charles et al. 2003; Kim et al. 1990; de Lanerolle 2012). The right 
panel of Figure 7 exhibits DG granular cells at higher magnification. In the PMC specimen 
the immunoreactivity with all three antibodies was present exclusively in the cell somata. In 
TLE-HS sections neuronal loss was evident, in addition the granule cells were smaller and 
more dispersed, immunolabelling was more intense.  
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Most of the pyramidal neurons in CAs areas and granule cells in DG were immunopositive. 
In addition, supported by recent evidence (Huyghe et al. 2014), some interneurons and 
possibly some astrocytes appeared immunopositive to the GABAB antibodies. It would be 
appropriate in future to perform double fluorescent immunostaining to verify which 
subpopulation of neurons and glia express GABAB receptors. 
 
4. DISCUSSION 
Previous studies have indicated that changes in the GABAB receptors subunits could be 
implicated in the pathophysiology of pharmaco-resistant TLE associated with HS (Billinton 
et al. 2001; Fürtinger et al. 2003b; Princivalle et al. 2003). Therefore, studying GABAB 
receptor protein expression may provide an important contribution to our understanding of 
one of the most important mechanisms implicated in temporal lobe epilepsy.  
 
The qRT-PCR results obtained in this study showed that there is no major difference in 
GABAB expression between TLE-HS and PMC samples. This is in agreement with previous 
data (Billinton et al. 2001). In contrast, the TLE-STG samples demonstrated a higher 
expression of both subunits compared to TLE-HS and PMC samples. The quantitative 
Western blot perfectly mirrored the trend of PCR data for GABAB2, but not for GABAB1. 
Figure 2 and 3 clearly demonstrate that the GABAB2 subunit expression is significantly lower 
in TLE-HS samples compared to the bioptic TLE-STG, and higher compared to the PMC 
as well as the IHC shows. It is difficult to compare qRT-PCR GABAB2 mRNA to previous in 
situ hybridization data (Princivalle et al. 2003; Fürtinger et al. 2003b). However, overall both 
techniques indicate a higher expression of GABAB2 mRNAs in the epileptic hippocampi 
compared to the PMC control.  
The protein quantification obtained from qWB demonstrated that GABAB1 and GABAB2 
expression mirror the mRNA level in TLE-HS and TLE-STG. Visual comparison of the three 
proteins by IHC between PMC control and TLE-HS patients displayed a wide distribution 
of GABAB isoforms and subunits in both types of specimen. However, as previously 
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reported (Princivalle et al. 2003; Fürtinger et al. 2003b), the quantitative comparison 
showed that, despite neuronal loss in TLE-HS hippocampal samples, there was an 
increment of GABAB1b and GABAB2 protein expression per remaining neuron in the CA 
areas and DG, compared to the PMC samples.  
It may be argued that our findings are contradictory because the quantification of Western 
blot and IHC showed opposite trend for GABAB1a. However, it is important to point out that 
WB data represents the total GABAB1a expression as we used homogenates of 
hippocampal tissue containing neurones, microglia and astrocytes rather than just the 
neuronal portion. In contrast, the quantitative IHC data represent GABAB1a expression per 
neurone. Comparing the mRNA and protein expression in Figures 2 and 3, it is evident that 
the trend of the receptor subunits is the same, demonstrating that GABAB2 expression is 
very much lower in the hippocampi of pharmaco-resistant patients compared to TLE-STG. 
Previous binding and present immunohistochemical data in human hippocampal PMC 
control and epileptic specimens appear in reasonable agreement (Princivalle et al. 2002).  
In the IHC the higher expression of GABAB1b and GABAB2 in the surviving neurones of the 
DG reflects the mRNA per neurone levels reported elsewhere (Princivalle et al. 2003; 
Furtinger et al. 2003b). In addition, the GABAB receptor autoradiography binding assays, 
corrected for neuronal loss (Billinton et al. 2000; Princivalle et al. 2002), showed a 
significant increase in receptor density per neurone in specific hippocampal subregions of 
the TLE-HS compared to PMC samples. 
The lower expression of both GABAB receptor subunits in TLE-HS compared to TLE-STG, 
could indicate a decline in GABAB receptors which would provide an explanation for the 
compromised GABAB functionality previously reported in pharmacological and 
electrophysiological studies in animal model and in human TLE (Billinton et al. 2000; 
Princivalle et al. 2002; Fürtinger et al. 2003b; Mareš and Kubová 2015; Leung et al. 2016; 
Rocha et al. 2015). This may be affecting the formation of fully functional GABAB receptors: 
since the heterodimerisation of GABAB1 and GABAB2 in 1:1 stoichiometry is essential for 
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receptor trafficking and G-protein activation, the GABAB2 subunit could be a potential target 
for the development of new agonists or activating transcription factors drugs, which may 
have a major clinical impact on the treatment of pharmaco-resistant TLE-HS patients. 
However, there are other factors which could explain the reduced GABAergic inhibition (Gill 
et al. 2010; Armstrong et al. 2016), and there is a strong possibility of co-causation. 
 
The findings of this study could be interpreted in two different ways: GABAB protein 
expression in epileptogenic hippocampal tissue could be down-regulated (because of the 
higher expression in TLE-STG tissue) or it could be up-regulated (because of the lower 
expression in PMC tissue). The decision which explanation is more likely depends on the 
relative merits of the two non-epileptogenic “control”-tissues. Unfortunately, neither PMC 
nor non-spiking TLE-STG is a perfect match for the TLE-HS samples of interest for the kind 
of experiments conducted here. However, there is no real alternative in human studies and 
it is not the first time that neocortex (STG) has been used in studies on TLE (Teichgrӓber 
et al. 2009; Rocha et al. 2015). Even human non-epileptogenic hippocampi removed for 
other reasons (such as temporal lobe tumours) cannot be considered an ideal control tissue 
for TLE-HS samples (Kovács et al. 2012). Son et al. (2015) demonstrated that tissue 
surrounding or adjacent to a tumour is physiologically and molecularly perturbed by the 
tumour itself or by previous irradiation. 
In view of these difficulties, many studies investigating TLE pathophysiology have recently 
compared their results obtained in epileptogenic TLE specimens to other surgically 
resected samples such as neocortex. The strength of this approach includes the fact that 
both sample types contain the same DNA (reducing the risk of intersubject variability 
caused by gene-gene or gene-environment interactions) and that both samples were 
obtained and processed in the same way. This approach also avoids the difficulties 
associated with comparing TLE-HS tissue removed during epilepsy surgery with PMC-HS 
tissue possibly affected by an agonal state and post-mortem changes (Preece et al. 2003; 
Tomita 2004; Teichgrӓber et al., 2009; Rocha et al. 2015).  
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In this study, the expression of mature GABAB receptor proteins was investigated for the 
first time in TLE-HS, and both types of potential “control” tissues, surgically resected non-
spiking TLE-STG and PMC specimens.  
 
CONCLUSIONS 
In agreement with older studies, we found the overall expression of GABAB increased in 
TLE-HS versus PMC. If correct, this finding suggests that the previously reported reduction 
in slow IPSPs in TLE-HS cannot be explained by a decreased protein expression of the 
GABAB receptor subunit. Instead this neurophysiological observation could be due to other 
causes including post-translational modification of the GABAB protein. On the other hand, 
this study shows a lower expression of GABAB2 in TLE-HS samples than in non-
epileptogenic TLE-STG from the same patients. Considering that the PMC values were 
affected by agonal or post-mortem changes (or due to undetected differences in clinical or 
demographic factors between TLE-HS and PMC subjects) the TLE-STG samples may 
represent a more appropriate “control” tissue. If so, the downregulation of GABAB2 
transcription and GABAB2 mature protein subunit in TLE-HS could represent one of the 
reasons for the impaired GABAergic inhibition reported in epileptogenic hippocampal tissue 
in the literature.  
 
LIST OF ABBREVIATIONS 
CA   cornu ammonis 
GABA   -Aminobutyric acid 
GABAB  -Aminobutyric acid receptor B 
DG   dentate gyrus 
HS   hippocampal sclerosis 
IHC   immunohistochemistry 
IR   immunoreactivity 
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PMC   post-mortem control 
PMI   post-mortem interval 
TLE   temporal lobe epilepsy 
DG   dentate gyrus 
ROD   relative optical density 
STG   superior temporal gyrus 
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FIGURE LEGENDS 
Figure 1 Graphical representation of linear regression  
(A) shows the correlation between mRNA from PMC samples and age; (B) illustrates the 
correlation between mRNA from PMC samples and PMI. 
 
Figure 2 Quantitative real time PCR of GABAB mRNA receptor subunits. 
qRT-PCR mRNA expression of GABAB1 and GABAB2 in 26 TLE-HS, 11 TLE-STG and 10 
PM control using TaqMan gene expression Assays and Comparative delta Ct analysis (2-
∆CT) method. Statistical analysis: Kruskal-Wallis with Conover-Inman post hoc analysis test 
was used to identify significant differences between (* P ≤ 0.05, ** P < 0.01, *** P< 0.001). 
Data presented as Mean ± S.D. 
 
Figure 3 Qualitative and quantitative Western blot 
(A) Qualitative WB of GABAB1a, GABAB1b, GABAB2 and β-Actin, revealed by double 
labelling with IRDye 680 and IRDye 800 secondary antibodies. (B) Quantitative 
expression of GABAB1a, GABAB1b and GABAB2 relative to β-Actin. Bands quantification 
was done on Odyssey infrared imaging system and Image Studio lite 4.0 software. 
Statistical analysis: Kruskal-Wallis with Conover-Inman post hoc analysis test was used to 
identify significant differences between (* P ≤ 0.05, ** P < 0.01, *** P< 0.001). Data 
presented as Mean ± S.D. 
 
Figure 4 Qualitative immunohistochemistry 
Distribution of GABAB1a, GABAB1b and GABAB2 in PMC and TLE-HS hippocampi. 
Photomicrographs showing GABAB1a (A, D), GABAB1b (B, E) and GABAB2 (C, F) IR in 
three adjacent sections from a post-mortem control and TLE-HS specimen. GABAB2 show 
the highest immunosignal, GABAB1a demonstrated a lower immunoreactivity and GABAB1b 
displays the lowest immunopositivity. Scale bars represent 4mm in A, B, C and 8 mm in 
D, E, F (magnification 5X). 
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Figure 5 Quantitative immunohistochemistry 
(A) Neuronal densities obtained by adjacent section of both TLE-HS (n=6-11) and PMC 
(n=5) stained with Cresyl Violet/Luxol Fast blue and. (B, C) graphs illustrate the 
percentage of GABAB positive pyramidal and granular neurons respectively compared to 
PMC. (D, E) graphs show semi-quantitative expression in pyramidal and granular cells of 
GABAB subunits in 6 TLE-HS and 2 PMC. Semi-quantitative analysis obtained is 
expression of GABA subunits in ROD per neurones. Data presented as Mean ± S.D. 
The statistical test used was Kruskal-Wallis: for pairwise comparisons (Conover-Inman). 
 
Figure 6 Brightfield photomicrograph displaying immunoreactivity in PMC and TLE-
HS CA1 and CA2 
Photomicrographs showing the distribution of GABAB1a, GABAB1b, and GABAB2 in human 
PMC and TLE-HS patients in the pyramidal cells of the CA1 (panel A); CA2 (panel B); red 
harrows show glial cells. Scale bars: 120 µm.  
 
Figure 7 Brightfield photomicrograph displaying immunoreactivity in PMC and TLE-
HS CA3 and DG 
Photomicrographs showing the distribution of GABAB1a, GABAB1b, and GABAB2 in human 
PMC and TLE-HS patients in the pyramidal cells of the CA3 (panel A); DG (panel B); red 
harrows show glial cells. Scale bars: 120 µm.  
